368 related articles for article (PubMed ID: 7829409)
1. In-vitro activity of quinolones and macrolides against mycobacteria.
Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF
J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409
[TBL] [Abstract][Full Text] [Related]
2. CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum.
Barrett MS; Jones RN; Erwin ME; Koontz FP
Diagn Microbiol Infect Dis; 1992 Feb; 15(2):169-71. PubMed ID: 1315233
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of four fluoroquinolones against eighty-six isolates of mycobacteria.
Texier-Maugein J; Mormède M; Fourche J; Bébéar C
Eur J Clin Microbiol; 1987 Oct; 6(5):584-6. PubMed ID: 3125050
[TBL] [Abstract][Full Text] [Related]
4. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to new macrolides, new quinolones, and antituberculous drugs on Dubos agar medium].
Ogawa K; Miwa T; Sasamoto M; Sasaki T; Tsuda M; Honda K; Furui H; Torii K; Takagi K
Kekkaku; 1992 Nov; 67(11):735-8. PubMed ID: 1487866
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis.
Hoffner SE; Gezelius L; Olsson-Liljequist B
J Antimicrob Chemother; 1997 Dec; 40(6):885-8. PubMed ID: 9462443
[TBL] [Abstract][Full Text] [Related]
6. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin.
Vacher S; Pellegrin JL; Leblanc F; Fourche J; Maugein J
J Antimicrob Chemother; 1999 Nov; 44(5):647-52. PubMed ID: 10552981
[TBL] [Abstract][Full Text] [Related]
7. In-vitro activities of quinolones against mycobacteria.
Garcia-Rodriguez JA; Gomez Garcia AC
J Antimicrob Chemother; 1993 Dec; 32(6):797-808. PubMed ID: 8144420
[TBL] [Abstract][Full Text] [Related]
8. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S
Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351
[TBL] [Abstract][Full Text] [Related]
9. [Antimycobacterial activities of a new quinolone, sparfloxacin].
Tomioka H; Sato K; Saito H
Kekkaku; 1991 Oct; 66(10):643-9. PubMed ID: 1660089
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].
Kawahara S; Tada A; Nagare H
Kekkaku; 2001 Apr; 76(4):357-62. PubMed ID: 11398326
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid.
Witzig RS; Franzblau SG
Antimicrob Agents Chemother; 1993 Sep; 37(9):1997-9. PubMed ID: 8239620
[TBL] [Abstract][Full Text] [Related]
12. Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.
Rastogi N; Goh KS; Bryskier A; Devallois A
Antimicrob Agents Chemother; 1996 Nov; 40(11):2483-7. PubMed ID: 8913450
[TBL] [Abstract][Full Text] [Related]
13. Preliminary study of the in vitro activity of irloxacin against mycobacteria.
Casal M; Gutierrez J; Ruiz P; Moreno G
Chemotherapy; 1995; 41(3):204-7. PubMed ID: 7656667
[TBL] [Abstract][Full Text] [Related]
14. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
Tomioka H
Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
[TBL] [Abstract][Full Text] [Related]
15. [In vitro antimycobacterial activity of a new quinolone, NM394].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 Aug; 68(8):517-20. PubMed ID: 8397311
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.
Molina-Torres CA; Ocampo-Candiani J; Rendón A; Pucci MJ; Vera-Cabrera L
Antimicrob Agents Chemother; 2010 May; 54(5):2188-90. PubMed ID: 20231398
[TBL] [Abstract][Full Text] [Related]
17. Comparative in-vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp.
Van Caekenberghe D
J Antimicrob Chemother; 1990 Sep; 26(3):381-6. PubMed ID: 2228828
[TBL] [Abstract][Full Text] [Related]
18. [In vitro antimycobacterial activity of a new quinolone, T-3761].
Tomioka H; Sato K; Saito H
Kekkaku; 1995 Feb; 70(2):97-101. PubMed ID: 7699982
[TBL] [Abstract][Full Text] [Related]
19. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin.
Gorzynski EA; Gutman SI; Allen W
Antimicrob Agents Chemother; 1989 Apr; 33(4):591-2. PubMed ID: 2524998
[TBL] [Abstract][Full Text] [Related]
20. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355).
Saito H; Sato K; Tomioka H; Dekio S
Tuber Lung Dis; 1995 Oct; 76(5):377-80. PubMed ID: 7495996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
